Kaos Capital Demands Capricor Therapeutics Board Changes and Capital Preservation Plan
Investment firm Kaos Capital has requested an immediate meeting and changes to Capricor Therapeutics' board, along with a capital preservation strategy.
Kaos Capital Ltd., a significant shareholder in Capricor Therapeutics (NASDAQ: CAPR), has issued a demand for an immediate shareholder meeting and changes to the company's board of directors. The investment firm also called for a capital preservation plan.
The firm cited concerns over the company's performance and financial management in its communication. Kaos Capital believes that the current board has not adequately represented shareholder interests and proposes that the board's composition be revised.
While specific details regarding the proposed board changes or the capital preservation strategy have not been fully disclosed, Kaos Capital is expected to present its proposals at the forthcoming shareholder meeting.
Capricor Therapeutics is a biotechnology company focused on developing treatments for rare diseases. The actions by Kaos Capital suggest a potential proxy fight or pressure campaign aimed at influencing the company's strategic direction and financial health.